Education
About Us
Working with TipRanks
Follow Us
Cardiol Therapeutics (CRDL)
NASDAQ:CRDL
CRDL Stock Chart & Stats
$1.04
-$0.03(-2.19%)
At close: 4:00 PM EST
$1.04
-$0.03(-2.19%)
Day’s Range― - ―
52-Week Range$0.77 - $2.24
Previous Close$1.33
Volume248.87K
Average Volume (3M)757.11K
Market Cap
$87.08M
Enterprise Value$134.86M
Total Cash (Recent Filing)$18.20M
Total Debt (Recent Filing)$142.55K
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Nov 18, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding83,729,450
10 Day Avg. Volume675,449
30 Day Avg. Volume757,113
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.29K
Enterprise Value/Ebitda-3.38
Forecast
1Y Price Target
$8.80Price Target Upside746.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe ARCHER study results bring important, additional proof-of-concept data on the anti-inflammatory effect of CardiolRx in a second indication.
Drug EfficacyCardiolRx shows potential in achieving the historically difficult goal of reducing left ventricular mass (LVM).
Market ValuationCRDL's current market cap does not reflect the positive outcomes of the ARCHER trial, suggesting an undervaluation of the stock.
Safety ProfileCardiolRx was well tolerated with no new safety signals observed, adding to its growing clinical profile and supporting continued development in various heart conditions.
Bears Say
Endpoint ResultsNo significant difference was observed in the second primary endpoint of global longitudinal strain (GLS).
Statistical SignificanceWhile CardiolRx showed a 'notable improvement' in extracellular volume (ECV), one of the two primary endpoints, the measure was NOT statistically significant at p=0.0538.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was $0.77 and its highest was $2.24 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is $87.08M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 33 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.071 earnings per share for the quarter, beating the consensus estimate of -$0.088 by $0.016.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.08.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 83,729,450 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -$0.071 in its last earnings report, beating expectations of -$0.088. Following the earnings report the stock price went down -2.239%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in CRDL
Cardiol Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.80 (746.15% Upside)
$8.80 (746.15% Upside)
Blogger Sentiment
Bullish
CRDL Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.47%
12-Months-Change
Fundamentals
Return on Equity
-271.56%
Trailing 12-Months
Asset Growth
-24.01%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
$8.80
▲(746.15% Upside)
Technical Analysis
Theratechnologies
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
BioNxt Solutions
―
Ownership Overview
3.92% Insiders
0.06% Mutual Funds
6.39% Other Institutional Investors
88.90% Public Companies and
Individual Investors